We are live on ! Find out more
AVNS icon

Avanos Medical

257 hedge funds and large institutions have $631M invested in Avanos Medical in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 72 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $510M → $631M (+$121M)

1% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 72

1.1% less ownership

Funds ownership: 97.78%96.68% (-1.1%)

6% less funds holding

Funds holding: 274257 (-17)

29% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 42

Holders
257
Holders Change
-17
Holders Change %
-6.2%
% of All Funds
3.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
30
Increased
71
Reduced
72
Closed
42
Calls
$217K
Puts
Net Calls
+$217K
Net Calls Change
+$158K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$95.9M +$1.25M +92,822 +1%
T. Rowe Price Investment Management
2
T. Rowe Price Investment Management
Maryland
$74.7M +$11.6M +860,154 +19%
Brown Advisory
3
Brown Advisory
Maryland
$31.3M +$3.98M +295,396 +15%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$28.8M -$1.42M -105,175 -5%
AC
5
Armistice Capital
New York
$28M -$16.2M -1,200,000 -38%
State Street
6
State Street
Massachusetts
$27.6M +$239K +17,738 +0.9%
VCM
7
Vanguard Capital Management
Pennsylvania
$27.6M +$26.6M +1,971,965 New
VPM
8
Vanguard Portfolio Management
Pennsylvania
$17.4M +$16.7M +1,239,295 New
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$17M +$3.53M +261,955 +27%
Thrivent Financial for Lutherans
10
Thrivent Financial for Lutherans
Minnesota
$16.6M +$13.1M +975,741 +460%
BCM
11
Boone Capital Management
Georgia
$16.6M +$16M +1,184,909 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$15.3M +$131K +9,731 +0.9%
Charles Schwab
13
Charles Schwab
California
$14.8M +$234K +17,400 +2%
CEI
14
Clark Estates Inc
New York
$11.8M -$591K -43,880 -5%
Morgan Stanley
15
Morgan Stanley
New York
$11.6M -$3.59M -266,374 -24%
AQR Capital Management
16
AQR Capital Management
Connecticut
$9.61M -$491K -36,446 -5%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$9.41M -$7.26M -539,043 -45%
Ameriprise
18
Ameriprise
Minnesota
$8.19M +$22.8K +1,692 +0.3%
Diamond Hill Capital Management
19
Diamond Hill Capital Management
Ohio
$8.04M +$865K +64,238 +13%
RA
20
Royce & Associates
New York
$7.2M +$6.1M +453,000 +746%
Northern Trust
21
Northern Trust
Illinois
$6.85M +$215K +15,940 +3%
Goldman Sachs
22
Goldman Sachs
New York
$6.74M +$397K +29,497 +7%
Citadel Advisors
23
Citadel Advisors
Florida
$6.66M -$46.1K -3,424 -0.7%
PAIM
24
Punch & Associates Investment Management
Minnesota
$6.12M +$2.25M +167,085 +62%
ECM
25
ExodusPoint Capital Management
New York
$5.91M -$2.22M -164,981 -28%

AVNS Hedge Fund Activity: Q1 2026 in Review

257 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Avanos Medical (AVNS) for Q1 2026, worth a combined $631M — up 24% from $510M a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of AVNS and 30 opened new positions — a net loss of 12 holders — while 72 trimmed existing stakes and 71 added.

The largest buyer was Boone Capital Management, opening a new position worth an estimated $16M. The largest seller was Armistice Capital, cutting an estimated $16.2M.

  • 257 institutional investors held Avanos Medical (AVNS) as of Q1 2026, down from 274 in Q4 2025.
  • Funds reported $631M of Avanos Medical stock for Q1 2026, up 24% quarter-over-quarter.
  • 30 funds opened new Avanos Medical positions in Q1 2026 and 42 closed out, a net change of -12 holders.
  • The largest Avanos Medical buyer in Q1 2026 was Boone Capital Management, an estimated $16M added.
  • The largest Avanos Medical seller in Q1 2026 was Armistice Capital, an estimated $16.2M sold.

Based on aggregated 13F filings for Q1 2026.